Glioblastoma patients in 2026 can access personalized immunotherapy through specialized cancer centers offering clinical trials that customize vaccines or cell therapies based on individual tumor molecular profiles. Key Takeaways Personalized glioblastoma immunotherapy remains investigational in 2026, accessible through clinical trials involving tumor sequencing and patient-specific vaccine or cell therapy manufacturing Three protocol types dominate the landscape: dendritic c

CAR-T cell therapy for lung cancer remains investigational in 2026, yet select centers now coordinate clinical trial access alongside conventional surgery, chemotherapy, and radiation under unified care teams. Key Takeaways CAR-T therapy for lung cancer is accessed through clinical trials and investigational protocols in 2026, not approved routine treatment pathways True integration requires multidisciplinary tumor boards coordinating immunotherapy specialists with thoracic s